Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement regarding targeted cancer therapy. This new antibody-drug conjugate joins a monoclonal antibody specifically directed at HER-2 https://www.targetmol.com/compound/datopotamab